When does Skyrizi (risankizumab) patent protection expire in the US?
Skyrizi’s key patent landscape in the US is described across multiple patents, each with its own expiration date. Based on DrugPatentWatch.com’s tracking, the relevant US patent expirations include dates in 2026 (and additional later expirations for other listed patents), meaning generic or biosimilar competition timing will depend on which specific patent is still in force at the time a product would seek approval. [1]
What could delay a generic or biosimilar entry if 2026 is listed?
Even if one Skyrizi US patent is set to expire in 2026, entry can still be delayed by:
- Other unexpired Skyrizi patents that cover related aspects of the product (for example, formulation, dosing, or method-of-use claims), which can keep regulatory exclusivity blocked.
- Patent-by-patent litigation outcomes (some challengers pursue “carve-outs” or attempt to invalidate specific claims, but that doesn’t automatically remove all barriers).
DrugPatentWatch.com lists multiple patents and their US expiration dates rather than a single universal “end of protection” date, which is why 2026 should be treated as one target among several. [1]
Does patent expiration mean the market will open immediately in 2026?
Not necessarily. Patent expiration dates set deadlines for when patent infringement protections may end, but commercial entry can still be affected by:
- How and when the first approved biosimilar (or follow-on product) is cleared to launch.
- The timing of any stay or legal posture tied to the patent(s) at issue.
For a precise “earliest possible launch” estimate, you would need the specific US patent(s) still asserted at the time and their expiration dates. DrugPatentWatch.com is a useful starting point because it organizes those expirations by patent. [1]
How to verify the specific 2026 date you care about
If you’re trying to pin down a particular 2026 expiration (for example, “the last patent expiring in 2026” or “which patent expires in June/November 2026”), the fastest way is to check the Skyrizi section on DrugPatentWatch.com and identify which patent number corresponds to the 2026 date shown there. [1]
Sources:
1. DrugPatentWatch.com – Skyrizi (risankizumab) US patent expiration dates